Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 16/20 | 0.46 |
| ▸ | MTOR | P42345 | 14/20 | 0.46 |
| ▸ | AKT1 | P31749 | 4/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RICTOR | Q6R327 | 2/20 | 0.39 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.39 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 0.39 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855456 | 0.88 | PIK3CA (0.54) | PIK3CAMTORAKT1PDE10APIK3R1 | |
| SCHEMBL856368 | 0.83 | MTOR (0.60) | PIK3CAMTORAKT1PIK3R1PIK3CB | |
| SCHEMBL855462 | 0.78 | PIK3CA (0.57) | PIK3CAMTORAKT1PDE10ARAF1 | |
| SCHEMBL855848 | 0.78 | PIK3CA (0.74) | PIK3CAMTORPIK3R1PIK3CBRICTOR | |
| SCHEMBL4441803 | 0.76 | HTT (0.45) | PIK3CAMTORAKT1PDE10ARAF1 | |
| SCHEMBL856846 | 0.75 | PIK3CA (0.59) | PIK3CAMTORPIK3CB | |
| SCHEMBL10327733 | 0.71 | PIK3CA (0.65) | PIK3CAMTORAKT1PIK3R1RAF1 | |
| SCHEMBL855868 | 0.71 | PIK3CA (0.68) | PIK3CAMTORPIK3R1PIK3CBRICTOR | |
| SCHEMBL856369 | 0.70 | PDE10A (0.46) | PIK3CAMTORAKT1PDE10ARAF1 | |
| SCHEMBL10327577 | 0.68 | MTOR (0.68) | PIK3CAMTORPIK3R1PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| EP-2118087-B1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| EP-2118087-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008098058-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | PI4KA, PI4KB, PI4K2A | PIK3CA 5/4885MTOR 64/4885AKT1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.